Key result
Restrictive annuloplasty improves functional class and LV function in chronic MR with ~3% 30-day mortality.
Why the study?
The early and late outcomes of restrictive mitral valve annuloplasty in patients with chronic mitral regurgitation and advanced ischemic or dilated cardiomyopathy were not well characterized.
Does restrictive mitral valve annuloplasty improve survival, symptoms, and LV function in patients with cardiomyopathy and chronic severe mitral regurgitation?
Cohort (n=121)
Does restrictive mitral valve annuloplasty improve survival, symptoms, and LV function in patients with cardiomyopathy and chronic severe mitral regurgitation?
Restrictive mitral valve annuloplasty safely corrects chronic MR and improves contractility in cardiomyopathy patients, though continuous reverse remodeling is primarily seen in ischemic patients undergoing concomitant CABG.
Answers are grounded in this paper and cite their sources.
May improve symptoms and LV function in cardiomyopathy with MR; hypothesis-generating for remodeling and survival, pending RCTs.
OBJECTIVE: This study investigated the early and late results of restrictive mitral valve (MV) annuloplasty in patients with chronic mitral regurgitation (MR) and advanced ischemic (ICM) or dilated cardiomyopathy (DCM). METHODS: From October 2001 to September 2006, 121 patients (age: 69 +/- 9 years) with a left ventricular ejection fraction (LVEF) of 30 +/- 9 % and chronic MR grade 3 - 4 (ICM: n = 102, DCM: n = 19) underwent restrictive prosthetic ring annuloplasty (downsizing of 2.7 +/- 0.8 ring sizes). Eighty-five ICM-patients had indications for concomitant coronary artery bypass grafting (CABG). All patients were restudied at 7 +/- 1 days, 3 +/- 1 and 30 +/- 12 months after surgery to assess survival, residual MR, New York Heart Association (NYHA) class and left ventricular (LV) function (end-systolic/end-diastolic dimensions/volume indexes and LVEF). Data were analyzed exploratively. RESULTS: 30-day mortality was 3.3 %; survival at follow-up was 95 % and 91 %, respectively. Postoperative recurrence of significant MR (> grade 2) was absent in all patients. NYHA class, LV dimensions/volume indexes and LVEF improved significantly after surgery in both groups ( P < 0.0005). A prediction of continuous postoperative improvement of myocardial function in the sense of reverse remodeling could be demonstrated by univariate logistic regression for ischemic etiology and concomitant CABG ( P = 0.0001). In DCM-patients or ICM-patients without CABG, the postoperative benefit on myocardial function was limited. CONCLUSION: Restrictive mitral valve (MV) annuloplasty corrected chronic MR in cardiomyopathy patients with low mortality and improved contractility. Surgery also prevented recurrence of significant MR, although the phenomenon of postoperative continuous reverse myocardial remodeling could not be verified in cases with a non-ischemic etiology or ICM without concomitant CABG.
No takes yet. Share an insight, caveat, or question.
Geidel et al. (2008) conducted a cohort in chronic mitral regurgitation and advanced ischemic or dilated cardiomyopathy (n=121). Restrictive mitral valve annuloplasty was evaluated on survival, residual MR, NYHA class and left ventricular function (p=<0.0005). Restrictive mitral valve annuloplasty in patients with cardiomyopathy and chronic MR yielded 3.3% 30-day mortality and improved functional class and LV function.
Synapse has enriched 10 related papers. Consider them for comparative context: